New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma

Journal of Gastroenterology

Volumn 49, Issue 2, 2014, Pages 165-172

  Patel, Tushar ^a  

^a MAYO CLINIC   (United States)

Author keywords

Biliary tract cancers; Cholangiocytes; Liver cancers

Indexed keywords

CETUXIMAB; CISPLATIN; ERLOTINIB; GEMCITABINE; OXALIPLATIN; SELUMETINIB; SORAFENIB; SUNITINIB; TRANSCRIPTOME;

BILE DUCT CARCINOMA; BILIARY TRACT INFLAMMATION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CELL SIGNALING ASSAY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; EPIGENETICS; GALLBLADDER CANCER; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; INTROSPECTION; LABORATORY TEST; LIVER CELL CARCINOMA; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NOMENCLATURE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

ASBESTOS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL TRANSFORMATION, NEOPLASTIC; CHOLANGIOCARCINOMA; HUMANS; LIVER CIRRHOSIS; MOLECULAR TARGETED THERAPY; OCCUPATIONAL EXPOSURE; RISK FACTORS; SIGNAL TRANSDUCTION; TRANSCRIPTOME; VOLATILE ORGANIC COMPOUNDS;

EID: 84896723581     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0894-y     Document Type: Review

References (57)

1. Patel T. Cholangiocarcinoma - controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189-200.
2. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 2010;42(4):253-60.
3. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10 (Epub 2002/05/07).
4. von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismuller TJ, Wedemeyer H, et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol. 2011;46(9):1092-8 (Epub 2011/06/23).
5. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33(6):1353-7 (Epub 2001/06/08).
6. Braconi C, Patel T. Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am. 2010;24(4):871-884, vii (Epub 2010/10/13).
7. Miller G, Socci ND, Dhall D, D'Angelica M, DeMatteo RP, Allen PJ, et al. Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res CR. 2009;28:62 (Epub 2009/05/14).
8. Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007;102(5):1016-21 (Epub 2007/02/28).
9. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang Y, et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma - focus on East and South-Eastern Asia. Asian Pac J Cancer Prev APJCP. 2010;11(5):1159-66 (Epub 2011/01/05).
10. Razumilava N, Gores GJ. Classification, Diagnosis, and Management of Cholangiocarcinoma. Clin Gastroenterol Hepatol. 2012 (Epub 2012/09/18).
11. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(9):512-22 (Epub 2011/08/03).
12. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepato Biliary Pancreat Surg. 2003;10(4):288-91 (Epub 2003/11/05).
13. Sempoux C, Jibara G, Ward SC, Fan C, Qin L, Roayaie S, et al. Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis. 2011;31(1):49-60 (Epub 2011/02/24).
14. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010;2(12):419-27 (Epub 2010/12/31).
15. Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol. 2(11):407-16.
16. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173-84 (Epub 2011/04/14).
17. Kaewpitoon N, Kaewpitoon SJ, Pengsaa P, Sripa B. Opisthorchis viverrini: the carcinogenic human liver fluke. WJG. 2008;14(5):666-74 (Epub 2008/01/22).
18. Shin HR, Lee CU, Park HJ, Seol SY, Chung JM, Choi HC, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol. 1996;25(5):933-40 (Epub 1996/10/01).
19. Honjo S, Srivatanakul P, Sriplung H, Kikukawa H, Hanai S, Uchida K, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer. 2005;117(5):854-60 (Epub 2005/06/16).
20. Soreide K, Korner H, Havnen J, Soreide JA. Bile duct cysts in adults. British J Surg. 2004;91(12):1538-48 (Epub 2004/11/19).
21. Kumagai S, Kurumatani N, Arimoto A, Ichihara G. Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane. Occup Environ Med. 2013;70(7):508-10 (Epub 2013/03/16).
22. Brandi G, Di Girolamo S, Farioli A, de Rosa F, Curti S, Pinna AD, et al. Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis. CCC. 2013;24(5):911-8 (Epub 2013/02/15).
23. Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. CCC. 2001;12(10):959-64 (Epub 2002/01/26).
24. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology. 2009;49(1):116-23 (Epub 2008/12/17).
25. Lee TY, Lee SS, Jung SW, Jeon SH, Yun SC, Oh HC, et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol. 2008;103(7):1716-20.
26. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128(3):620-6 (Epub 2005/03/15).
27. Yamamoto S, Kubo S, Hai S, Uenishi T, Yamamoto T, Shuto T, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci. 2004;95(7):592-5 (Epub 2004/07/13).
28. Yu TH, Yuan RH, Chen YL, Yang WC, Hsu HC, Jeng YM. Viral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expression. Mod Pathol. 24(6):810-9.
29. Zhou YM, Yin ZF, Yang JM, Li B, Shao WY, Xu F, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. WJG. 2008;14(4):632-5 (Epub 2008/01/19).
30. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012;57(1):69-76 (Epub 2012/03/17).
31. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142(4):1021-1031 e15 (Epub 2011/12/20).
32. Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012;28(3):266-72 (Epub 2012/03/08).
33. Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013 (Epub 2013/01/16).
34. Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ, et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res. 2010;70(8):3034-41 (Epub 2010/04/17).
35. Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of mir-200c and EMT in intrahepatic cholangiocarcinoma. Hepatology. 2012 (Epub 2012/06/19).
36. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12(4):410-6 (Epub 2006/03/15).
37. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144(4):829-40 (Epub 2013/01/09).
38. Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2012;9(1):44-54 (Epub 2011/12/07).
39. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3(6):636-47 (Epub 2013/04/06).
40. Zender S, Nickeleit I, Wuestefeld T, Sorensen I, Dauch D, Bozko P, et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell. 2013;23(6):784-95 (Epub 2013/06/04).
41. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012;122(8):2911-5 (Epub 2012/07/17).
42. Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest. 2012 (Epub 2012/10/02).
43. Namwat N, Puetkasichonpasutha J, Loilome W, Yongvanit P, Techasen A, Puapairoj A, et al. Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases. J Gastroenterol. 2011;46(5):664-75 (Epub 2010/11/16).
44. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene. 2008;27(3):378-86 (Epub 2007/07/11).
45. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 2006;66(21):10517-24 (Epub 2006/11/03).
46. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology. 2007;132(1):384-96 (Epub 2007/01/24).
47. Braconi C, Swenson E, Kogure T, Huang N, Patel T. Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. PloS one. 2010;5(12):e15195 (Epub 2010/12/24).
48. Stuebs P, Habermann P, Garlipp B, Schuette K, Zierau K, Lippert H, et al. Developments of treatment of advanced intrahepatic cholangiocarcinoma: an analysis of systemic and local therapy modes in 57 patients. J Clin Oncol. 2012;30(Suppl 4):abstr 346.
49. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7(6):593-600.
50. Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol. 2004;15(3):478-83.
51. Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P, et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer. 2005;41(3):398-403 (Epub 2005/02/05).
52. Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005;92(9):1650-4.
53. Takada T, Nimura Y, Katoh H, Nagakawa T, Nakayama T, Matsushiro T, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology. 1998;45(24):2020-6 (Epub 1999/02/10).
54. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. N Engl J Med. 2010;362(14):1273-81.
55. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer. 2009;101(4):621-7 (Epub 2009/08/13).
56. Sugiyama H, Onuki K, Ishige K, Baba N, Ueda T, Matsuda S, et al. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. J Gastroenterol. 2011;46(6):779-89 (Epub 2011/02/19).
57. Voss JS, Holtegaard LM, Kerr SE, Fritcher EG, Roberts LR, Gores GJ, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Human pathology. 2013 (Epub 2013/02/09).